Reviva Pharmaceuticals
19925 Stevens Creek Blvd.
Suite 100
Cupertino
California
95014
United States
80 articles about Reviva Pharmaceuticals
-
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
3/28/2024
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at the 2024 Schizophrenia International Research Society (SIRS) Annual Meeting, to be held April 3-7, 2024, in Florence, Italy.
-
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
3/26/2024
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting a poster at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting, to be held in Colorado Springs, CO, USA on March 27-29, 2023.
-
Reviva to Present at the UBS Virtual CNS Day
3/11/2024
Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a Fireside Chat at the UBS Virtual CNS Day, taking place virtually March 18, 2024.
-
Reviva to Present at the 36th Annual ROTH Conference
3/7/2024
Reviva Pharmaceuticals Holdings, Inc. today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 36th Annual ROTH Conference, taking place March 17-19, 2024.
-
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
2/20/2024
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 2024 BIO CEO & Investor Conference, taking place February 26-27, 2024, in New York, NY.
-
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
2/6/2024
Reviva Pharmaceuticals Holdings, Inc. today announced that it will host a key opinion leader (KOL) event on Thursday, February 15, 2024 at 12:00 PM ET.
-
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
1/25/2024
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company") today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will participate in a fireside chat moderated by Jim Molloy, Senior Analyst at Alliance Global Partners, at the Lytham Partners 2024 Investor Select Conference.
-
Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones
1/4/2024
Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system, inflammatory and cardiometabolic diseases, provided program updates and announced upcoming key milestones.
-
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
12/11/2023
Reviva Pharmaceuticals Holdings, Inc. today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on December 14th, 2023.
-
Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
11/30/2023
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, and Narayan Prabhu, CFO of Reviva, will participate in The Benchmark Company’s Discovery One-on-One Investor Conference, taking place December 7, 2023 in New York, NY.
-
Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11/20/2023
Reviva Pharmaceuticals Holdings, Inc. announced that it has closed its previously announced registered direct offering with several healthcare-focused institutional investors.
-
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11/16/2023
Reviva Pharmaceuticals Holdings, Inc. announced that it has entered into definitive agreements with several healthcare-focused institutional investors, and an investment vehicle managed by a firm affiliated with a member of the Company’s Board of Directors.
-
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
11/14/2023
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today reported financial results for the third quarter ended September 30, 2023 and summarized recent business highlights.
-
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
10/30/2023
Reviva Pharmaceuticals Holdings, Inc. today announced positive topline results and successful completion of its pivotal Phase 3 RECOVER trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine, a serotonin-dopamine signaling modulator in adults with schizophrenia.
-
Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia
9/25/2023
Reviva Pharmaceuticals Holdings, Inc. announced that the last patient in its global pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia has now completed the study.
-
Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
9/7/2023
Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will both present and participate in a conference panel at the H.C. Wainwright 25th Annual Global Investment Conference, taking place September 11-13, 2023 virtually and in New York City, New York.
-
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
8/17/2023
Reviva Pharmaceuticals Holdings, Inc. announced that enrollment is complete in the pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia, with 402 patients enrolled at multiple sites in the United States, Europe, and Asia.
-
Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights
8/14/2023
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today reported financial results for the second quarter ended June 30, 2023 and summarized recent business highlights.
-
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August
7/31/2023
Reviva Pharmaceuticals Holdings, Inc. today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at two upcoming investor conferences to be held in August 2023.
-
Reviva Pharmaceuticals to be Added to Russell Microcap® Index
6/26/2023
Reviva Pharmaceuticals Holdings, Inc. announced that the Company will be added to the Russell Microcap® Index, effective after the United States market opens on Monday, June 26, 2023, following the conclusion of the 2023 Russell indexes annual reconstitution.